S. Blum

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

L. Urban, K. O'Byrne, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.

C. Porta, M. Burotto, T. Choueiri, 2023, European urology oncology.

General population reference values for the Functional Assessment of Cancer Therapy‐Lung and PROMIS‐29

D. Cella, J. Penrod, N. Mohindra, 2023, Cancer medicine.

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

J. Ajani, Y. Janjigian, L. Wyrwicz, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214

R. Motzer, C. Ivanescu, F. Ejzykowicz, 2024, The oncologist.